Plant Name: Prunus persica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| FAAH; TERT; HPGD; ALOX12; CBR1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; USP2; UGT1A1; APEX1; | |
| TRPA1; | |
| FLT3; CDK1; GRK6; CDK6; | |
| CA2; CA1; CA12; CA9; CA5B; CA7; CA4; | |
| PPARA; PPARD; PPARG; | |
| KDM4E; | |
| PTGS1; XDH; | |
| HIF1A; TP53; NFKB1; | |
| ABCG2; | |
| LMNA; FABP5; CREB1; FABP3; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | UGT1A1 | UDP-glucuronosyltransferase 1-1 | P22309 | CHEMBL1287617 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | GRK6 | G protein-coupled receptor kinase 6 | P43250 | CHEMBL6144 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | CREB1 | Cyclic AMP-responsive element-binding protein 1 | P16220 | CHEMBL5587 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.517E-13 | 3.224E-10 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.963E-12 | 3.752E-09 | CA1, CA12, CA2, CA4, CA5B, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.162E-11 | 1.012E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.791E-11 | 1.444E-08 | CA1, CA12, CA2, CA4, CA5B, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.117E-11 | 1.646E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.361E-11 | 1.773E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.693E-11 | 2.437E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP3A4, PTGS1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.391E-11 | 4.350E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.935E-10 | 2.750E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.074E-09 | 1.263E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.516E-08 | 1.944E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.012E-07 | 1.149E-04 | CYP19A1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.914E-06 | 5.616E-04 | CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP3A4, FAAH, PTGS1, UGT1A1 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 3.525E-06 | 6.630E-04 | ALDH1A1, CYP1A1, CYP1B1, PPARD, UGT1A1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.532E-06 | 6.630E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 5.363E-06 | 9.385E-04 | CREB1, PPARA, PPARG, TP53, USP2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.695E-06 | 9.765E-04 | CA1, CA12, CA2, CA4, CA5B, CA7, CA9, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 6.567E-06 | 1.080E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 6.567E-06 | 1.080E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 7.178E-06 | 1.141E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 8.925E-06 | 1.369E-03 | ALOX12, ALOX15, HPGD |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.082E-05 | 1.592E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.082E-05 | 1.592E-03 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0014823; response to activity | 1.418E-05 | 2.016E-03 | CDK1, CREB1, HIF1A, PPARD |
| BP | GO:0008152; metabolic process | GO:0045834; positive regulation of lipid metabolic process | 1.625E-05 | 2.283E-03 | CREB1, FABP3, FLT3, PPARA, PPARG |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 1.757E-05 | 2.453E-03 | CREB1, CYP19A1, FFAR1, HIF1A, PPARD |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 1.804E-05 | 2.486E-03 | CREB1, PPARA, TERT |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.859E-05 | 2.546E-03 | AKR1B1, APEX1, CDK1, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.967E-05 | 2.627E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.967E-05 | 2.627E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.967E-05 | 2.627E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.967E-05 | 2.627E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.100E-05 | 2.772E-03 | CYP1A1, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.428E-05 | 3.147E-03 | HIF1A, TERT, TP53 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 2.700E-05 | 3.438E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.787E-05 | 3.508E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.144E-05 | 3.889E-03 | APEX1, CYP1A1, CYP1B1, FLT3, NFKB1, PPARG, UGT1A1 |
| BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 3.179E-05 | 3.889E-03 | CYP19A1, CYP1B1, UGT1A1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 3.179E-05 | 3.889E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 3.440E-05 | 4.162E-03 | CDK6, CREB1, FLT3, NFKB1, PPARD, PPARG, UGT1A1 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 3.606E-05 | 4.291E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.927E-05 | 4.622E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 4.069E-05 | 4.763E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 4.442E-05 | 5.145E-03 | CDK1, FLT3, PPARG, UGT1A1 |
| MF | GO:0005488; binding | GO:0035035; histone acetyltransferase binding | 4.569E-05 | 5.264E-03 | CREB1, HIF1A, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 4.677E-05 | 5.332E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 5.435E-05 | 6.069E-03 | CREB1, FABP3, FFAR1, PPARG |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 5.728E-05 | 6.299E-03 | AKR1B1, ALOX12, CDK1, FFAR4, HIF1A, LMNA, NFKB1, PPARD, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 6.093E-05 | 6.568E-03 | APEX1, CREB1, NFKB1, PPARG, TSHR |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 6.534E-05 | 6.856E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 6.534E-05 | 6.856E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 6.537E-05 | 6.856E-03 | ALOX12, CDK6, CYP19A1, FFAR4, HIF1A, LMNA, NFKB1, PPARA, PPARD, PPARG, TERT, TP53, XDH |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.534E-05 | 6.856E-03 | CYP1A1, CYP3A4 |
| MF | GO:0005488; binding | GO:0030332; cyclin binding | 6.970E-05 | 7.193E-03 | CDK1, CDK6, USP2 |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 7.046E-05 | 7.231E-03 | ALOX12, CA2, CDK1, CREB1, CYP1B1, HIF1A, LMNA, NFKB1, PPARD, PPARG, TERT, THPO |
| BP | GO:0008283; cell proliferation | GO:0048145; regulation of fibroblast proliferation | 7.215E-05 | 7.307E-03 | CDK6, CREB1, PPARG, TP53 |
| BP | GO:0002376; immune system process | GO:0045639; positive regulation of myeloid cell differentiation | 7.215E-05 | 7.307E-03 | CA2, CREB1, HIF1A, THPO |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 7.709E-05 | 7.750E-03 | CYP1A1, CYP1A2, HPGD, NFKB1, PPARD, UGT1A1 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 7.984E-05 | 7.938E-03 | AKR1B1, ALOX12, ALOX15, CYP19A1, CYP1A1, CYP3A4, PPARD, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0044242; cellular lipid catabolic process | 8.317E-05 | 8.232E-03 | CYP1B1, FAAH, FABP3, FABP5, PPARD |
| MF | GO:0003824; catalytic activity | GO:0051213; dioxygenase activity | 8.615E-05 | 8.450E-03 | ALOX12, ALOX15, KDM4E, PTGS1 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 9.785E-05 | 9.304E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 9.785E-05 | 9.304E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 9.785E-05 | 9.304E-03 | CYP1A1, CYP3A4 |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 9.785E-05 | 9.304E-03 | FABP3, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 9.785E-05 | 9.304E-03 | CA1, CA2 |
| BP | GO:0008283; cell proliferation | GO:2000648; positive regulation of stem cell proliferation | 1.008E-04 | 9.539E-03 | HIF1A, TERT, THPO |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.182E-15 | 7.446E-12 | CA1, CA12, CA2, CA4, CA5B, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.514E-15 | 1.044E-12 | CA12; CA1; CA5B; CA2; CA4; CA7; CA9 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.555E-13 | 3.166E-11 | CYP2C9; CBR1; CYP2A6; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.008E-11 | 4.670E-10 | CYP2C9; CBR1; CYP2A6; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.457E-10 | 8.539E-09 | CYP2C9; CYP2A6; UGT1A1; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.894E-09 | 1.965E-07 | CYP2C9; CBR1; ALOX15; ALOX12; CYP2C19; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.832E-08 | 4.373E-07 | CBR1; UGT1A1; ALOX15; AKR1B1; ALOX12; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.564E-09 | 1.825E-07 | UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.904E-08 | 3.308E-07 | CYP2C9; CYP2A6; UGT1A1; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.024E-09 | 1.965E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 7.923E-07 | 1.001E-05 | FABP3; FABP5; PPARG; PPARA; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.725E-06 | 9.329E-05 | CYP2C9; ALOX15; ALOX12; CYP2C19; PTGS1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.512E-05 | 5.473E-04 | CDK6; FLT3; PPARG; HIF1A; TP53; NFKB1; PPARD |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.219E-06 | 6.046E-05 | CYP2A6; UGT1A1; CYP3A4; XDH |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 8.930E-05 | 7.758E-04 | CREB1; PPARG; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.569E-04 | 1.212E-03 | CREB1; CDK6; CDK1; TP53; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 8.524E-05 | 7.758E-04 | HPGD; FLT3; PPARG; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.835E-04 | 3.200E-03 | CREB1; CDK6; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.912E-04 | 2.719E-03 | FLT3; NFKB1; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.653E-04 | 1.941E-03 | CYP1A1; CYP1B1; CYP19A1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.361E-04 | 1.113E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.022E-04 | 3.803E-03 | CDK6; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.293E-04 | 3.803E-03 | FLT3; TP53; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.085E-04 | 4.322E-03 | CDK6; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.532E-03 | 7.096E-03 | CREB1; PPARA; NFKB1; TSHR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.435E-03 | 7.096E-03 | CREB1; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.300E-03 | 6.694E-03 | CDK6; TP53; NFKB1 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 6.858E-04 | 3.972E-03 | CDK6; CDK1; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.455E-04 | 4.145E-03 | CA2; CYP3A4; ABCG2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.562E-03 | 1.113E-02 | CREB1; PPARA; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.912E-03 | 1.554E-02 | CREB1; TERT; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.392E-03 | 1.685E-02 | CREB1; PPARG; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.174E-03 | 1.844E-02 | LMNA; TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 3.687E-03 | 1.507E-02 | CDK6; CDK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.486E-03 | 1.685E-02 | PPARA; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.774E-03 | 1.746E-02 | CDK6; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.419E-03 | 2.231E-02 | CDK6; CYP1B1; TP53; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.032E-02 | 3.262E-02 | CREB1; CDK6; TP53; NFKB1 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 1.244E-02 | 3.678E-02 | CREB1; PPARG; TP53 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.110E-02 | 3.428E-02 | CDK1; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.405E-02 | 3.828E-02 | CDK1; TP53; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.152E-02 | 3.482E-02 | CDK6; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.655E-03 | 2.798E-02 | CDK6; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.655E-03 | 2.798E-02 | TSHR; PTGS1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.364E-02 | 3.791E-02 | CDK6; TP53 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.327E-02 | 3.791E-02 | PPARA; NFKB1 |
| hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 1.364E-02 | 3.791E-02 | CREB1; TSHR |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 6.683E-03 | 2.266E-02 | CREB1; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.382E-03 | 1.068E-02 | PPARG; TP53 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 3.655E-03 | 1.507E-02 | UGT1A1; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.499E-03 | 7.096E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.465E-07 | 2.036E-06 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; FLT3; FLT3; CA9; CDK1; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; PTGS1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; FLT3; FLT3; CA9; CDK1; NFKB1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; PTGS1; TRPA1; FAAH |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TERT |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; FAAH |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |